Shared on 01 Nov 25
Fair value Increased 6.58%Amneal Pharmaceuticals’ analyst price target has risen from $12.67 to $13.50, as analysts cite stronger revenue growth and an improved earnings outlook following the company’s recent results. Analyst Commentary Recent analyst updates indicate a mix of optimism and caution following Amneal Pharmaceuticals’ latest quarterly performance and forward guidance.
Shared on 17 Sep 25
Fair value Increased 5.56%Global Health Trends And Pipeline Launches Will Fuel Future Potential
Amneal Pharmaceuticals' consensus price target has been raised as analysts now assign a higher future P/E multiple, increasing their fair value estimate from $12.00 to $12.67. What's in the News Amneal received FDA approval for its sodium oxybate oral solution 500 mg/mL (generic for Xyrem) for narcolepsy, expanding beyond prior limited authorized generic distribution.
Shared on 01 May 25
Fair value Increased 1.69%Global Health Trends And Pipeline Launches Will Fuel Future Potential
Shared on 24 Apr 25
CREXONT And Metsera Partnerships Will Capitalize On Growing GLP-1 Market
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Fair value Increased 1.29%CREXONT And Metsera Partnerships Will Capitalize On Growing GLP-1 Market
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Decreased 0.85%CREXONT And Metsera Partnerships Will Capitalize On Growing GLP-1 Market
AnalystConsensusTarget has decreased profit margin from 4.8% to 3.1%, increased future PE multiple from 26.9x to 41.4x and decreased shares outstanding growth rate from 0.0% to 0.0%.
Shared on 02 Apr 25
Fair value Increased 2.44%CREXONT And Metsera Partnerships Will Capitalize On Growing GLP-1 Market
Shared on 26 Mar 25
CREXONT And Metsera Partnerships Will Capitalize On Growing GLP-1 Market
AnalystConsensusTarget made no meaningful changes to valuation assumptions.